Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma

Study Summary

This study will test whether a combination of two medicines, zilovertamab vedotin (ZV) and lenalidomide, can help people with peripheral T-cell lymphoma that has come back after treatment or has not responded to previous treatment. The combination, called "ZiVLen", is designed to provide an alternative treatment approach that may use less chemotherapy than standard regimens. Researchers will evaluate how well this treatment works in controlling the lymphoma and will also assess its safety and side effects. The study will collect research biospecimens (archival tissue, and onstudy blood and stool samples) to investigate whether there are any immune system changes in participants who's lymphoma responds to the treatment compared to those who do not. In addition, health related quality of life surveys (patient reported outcome measures \[PROMS\]) will be collected to better understand whether the treatment and/or trial has impacted the health related quality of life of participants in their own voice. The results of this study will help determine whether ZiVLen should be studied further in larger clinical trials.